Eddie Sullivan, SAB Biotherapeutics president and CEO

South Dako­ta-based Covid-19 trans­genic cow an­ti­body start­up claims its first PhI­II win

SAB Bio­ther­a­peu­tics, known for col­lect­ing and dis­till­ing an­ti­bod­ies from cows with hu­man­ized im­mune sys­tems, on Wednes­day said a Phase III tri­al it ran for its po­ten­tial Covid-tar­get­ed poly­clon­al an­ti­body demon­strat­ed ben­e­fit in sus­tained symp­tom res­o­lu­tion in pa­tients with the Omi­cron vari­ant.

The NIH-run study put the SAB treat­ment up against Re­gen­eron’s mon­o­clon­al an­ti­body — known as RE­GEN-COV, which was pulled from the mar­ket in Jan­u­ary 2022 due to its in­ef­fec­tive­ness against Omi­cron — in non-hos­pi­tal­ized peo­ple with Covid-19 who were at high-risk for se­vere out­comes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.